EV
$3.15
-0.05
(-1.56%)
As of Oct 5, 2026, 5:53 PM EDT
Price history
Evaxion A/S (EVAX) is trading down at $3.15 (-1.56%), as of the latest quote. It operates in the Health Care sector.
IPO: February 5, 2021 · $10.00 offering · NASDAQ · View IPO details →
Evaxion A/S revenue & net income history (FY2018–FY2025)
RevenueNet income
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | $0 | $73.0K | $3.34M | $7.53M |
| Growth (year over year) | — | — | — | — | — | — | +4480.8% | +125.1% |
| Operating income | −$5.63M | −$10.9M | −$16.6M | −$25.8M | −$25.3M | −$22.2M | −$14.7M | −$9.23M |
| Operating margin | — | — | — | — | — | −30406.8% | −440.6% | −122.7% |
| Net income | −$5.54M | −$11.2M | −$15.0M | −$24.5M | −$23.2M | −$22.1M | −$10.6M | −$7.71M |
| Net margin | — | — | — | — | — | −30308.2% | −316.0% | −102.4% |
| EPS (diluted) | −$0.43 | −$0.81 | −$0.97 | −$1.26 | −$0.98 | −$0.81 | — | — |
| Balance sheet | ||||||||
| Cash and equivalents | $7.43M | $9.56M | $5.83M | $32.2M | $13.2M | $5.58M | $5.95M | $23.2M |
| Total assets | — | $11.1M | $12.0M | $40.2M | $22.0M | $12.9M | $12.5M | $28.4M |
| Total liabilities | — | $1.72M | $4.93M | $7.73M | $13.7M | $17.6M | $14.1M | $11.4M |
| Shareholders' equity | −$931.0K | $9.36M | $7.04M | $32.4M | $8.30M | −$4.73M | −$1.65M | $17.0M |
| Cash flow | ||||||||
| Operating cash flow | −$1.99M | −$7.02M | −$12.4M | −$21.9M | −$25.8M | −$17.7M | −$12.9M | −$6.63M |
| Capital expenditure | $7.00K | $61.0K | $149.0K | $1.30M | $292.0K | $87.0K | $0 | $11.0K |
| Free cash flow | −$2.00M | −$7.08M | −$12.6M | −$23.2M | −$26.1M | −$17.8M | −$12.9M | −$6.64M |
RevenueNet income
| Q2 FY23Jun 2023 | Q4 FY23Dec 2023 | Q1 FY24†Mar 2024 | Q2 FY24Jun 2024 | Q4 FY24Dec 2024 | Q1 FY25†Mar 2025 | Q2 FY25Jun 2025 | Q4 FY25Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $51.0K | $154.0K | — | $0 | $37.0K | — |
| Growth (year over year) | — | — | — | — | — | −100.0% | −76.0% | — |
| Operating income | −$5.68M | — | −$4.40M | −$4.58M | — | −$3.87M | −$4.34M | — |
| Operating margin | — | — | −8619.6% | −2974.7% | — | — | −11729.7% | — |
| Net income | −$5.68M | — | $1.19M | −$6.20M | — | −$1.58M | −$4.83M | — |
| Net margin | — | — | 2341.2% | −4024.7% | — | — | −13056.8% | — |
| EPS (diluted) | −$0.21 | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash and equivalents | $7.12M | $5.58M | — | $7.99M | $5.95M | — | $14.7M | $23.2M |
| Total assets | $16.8M | $12.9M | — | $15.2M | $12.5M | — | $22.4M | $28.4M |
| Total liabilities | $14.2M | $17.6M | — | $14.0M | $14.1M | — | $16.2M | $11.4M |
| Shareholders' equity | $2.54M | −$4.73M | — | $1.25M | −$1.65M | — | $6.23M | $17.0M |
From Evaxion A/S's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Evaxion A/S
- Headquarters
- Hoersholm, Denmark From SEC filings, Oct 2026
Recent News (2)
-
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting COPENHAGEN, Denmark, October 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will prese…
-
Can Merck & Company (MRK)’s Stake in Evaxion A/S (EVAX) Validate the Potential of AI-Driven Vaccine Discovery?
Can Merck & Company (MRK)’s Stake in Evaxion A/S (EVAX) Validate the Potential of AI-Driven Vaccine Discovery?
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International